Legato Capital Management’s Pacira BioSciences PCRX Stock Holding History

Legato Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$778K	Sell	30,668 -8,339	-21%	-$197K	0.06%	428
2026 Q1	$882K	Sell	39,007 -8,182	-17%	-$182K	0.08%	324
2025 Q4	$1.22M	Sell	47,189 -9,242	-16%	-$220K	0.11%	306
2025 Q3	$1.45M	Buy	56,431 +15,568	+38%	+$382K	0.16%	195
2025 Q2	$977K	Hold	40,863	–	–	0.12%	281
2025 Q1	$1.02M	Sell	40,863 -14,040	-26%	-$336K	0.14%	246
2024 Q4	$1.03M	Hold	54,903	–	–	0.14%	285
2024 Q3	$826K	Buy	54,903 +1,990	+4%	+$34K	0.1%	351
2024 Q2	$1.51M	Buy	52,913 +22,497	+74%	+$640K	0.2%	174
2024 Q1	$889K	Buy	30,416 +19,248	+172%	+$591K	0.11%	302
2023 Q4	$377K	Buy	11,168 +1,563	+16%	+$45.7K	0.05%	468
2023 Q3	$295K	Buy	+9,605	New	+$346K	0.04%	480

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legato Capital Management's PCRX Position: Q2 2026 in Review

Legato Capital Management reduced its Pacira BioSciences (PCRX) stake by 21% in Q2 2026, selling an estimated $197K and leaving 30,668 shares worth $778K. The position accounts for 0.06% of the portfolio, ranked #428.

Legato Capital Management first reported a position in PCRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.51M in Q2 2024. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Legato Capital Management held 30,668 shares of Pacira BioSciences worth $778K as of Q2 2026.
Legato Capital Management sold 8,339 Pacira BioSciences shares in Q2 2026, an estimated $197K.
Pacira BioSciences made up 0.06% of Legato Capital Management's portfolio in Q2 2026, its #428 holding.
Legato Capital Management first reported a position in Pacira BioSciences in Q3 2023 and has held it in 12 quarters since.
Legato Capital Management's Pacira BioSciences position peaked at $1.51M in Q2 2024.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.